Retinoic Acid Homeostasis in Major Depression
Information source: Charite University, Berlin, Germany
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Major Depression
Phase: N/A
Status: Recruiting
Sponsored by: Charite University, Berlin, Germany Official(s) and/or principal investigator(s): Isabella Heuser, MD, PhD, Principal Investigator, Affiliation: Chair: Department of Psychiatry, Charité, CBF
Overall contact: Julian Hellmann-Regen, MD, Email: Julian.Hellmann@charite.de
Summary
It is hypothesized, that local retinoic acid (RA) homeostasis is functionally involved in
the pathophysiology of depression. In a cross-sectional analysis healthy controls and
depressed patients, serum RA status will be assessed.
Clinical Details
Official title: Retinoic Acid Homeostasis in Major Depression
Study design: Observational Model: Case Control, Time Perspective: Cross-Sectional
Primary outcome: Serum retinoic acid (RA) levels [nM]
Secondary outcome: Montgomery-Asberg Depression Rating Scale (MADRS)Serum retinoic acid (RA) levels [nM] Serum retinoic acid (RA) levels [nM] phenotyping of peripheral white blood cells Beck Depression Inventory (BDI) Investigation of RA homeostasis-related gene transcription in patient-derived cells.
Detailed description:
Retinoids comprise of a group of small-molecule derivatives of Vitamin A with retinoic acid
(RA) representing the biologically most active endogenous form. RA has multiple functions
central nervous system (CNS). It is hypothesized, that local RA homeostasis is functionally
involved in the pathophysiology of depression. In a cross-sectional analysis healthy
controls and depressed patients, serum RA status will be assessed.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
MDD-Group
Inclusion Criteria:
- depressive episode in the context of unipolar major depression
- at least 18 points or more on the BDI and HAMD-17
Exclusion Criteria:
- additional or comorbid axis-I or axis-II disorder current history of any neurological
or other serious medical condition
- any psychopharmacological treatment or substance use within the last two weeks or 5
half-lives (whichever is longer) of the respective substance
- any oral or topical application of retinoid-containing preparations within the last 3
months
Locations and Contacts
Julian Hellmann-Regen, MD, Email: Julian.Hellmann@charite.de
Department of Psychiatry, Charité - Campus Benjamin Franklin, Berlin 12203, Germany; Recruiting
Additional Information
Starting date: March 2015
Last updated: May 7, 2015
|